[Experimental study of CF chemotherapy, combined with another one chemotherapeutic drug against head and neck cancer cell lines].
Tsukuda
M
M
Department of Otorhinolaryngology, School of Medicine, Yokohama City University, Japan.
Mochimatsu
I
I
Kokatsu
T
T
Ito
K
K
Furukawa
S
S
Inoue
T
T
Watanabe
S
S
Sawaki
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D005047:Etoposide / Q000494:pharmacology; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology*; D006258:Head and Neck Neoplasms / Q000473:pathology*; D006801:Humans; D008727:Methotrexate / Q000494:pharmacology; D017663:Peplomycin; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014750:Vincristine / Q000494:pharmacology
D001761:Bleomycin; D017663:Peplomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate